The “IgGA” hybrid trastuzumab mediated an enhanced ADCC/ADCP activity against Her2 overexpressing cells and destroyed up to 50% SkBr3 breast cancer cells (via ADCC) and MDA-MB-453 cells (via ADCP) (60). This evidence concerns the gene ERBB2 and breast carcinoma.